Celgene

This study tests a new drug, BMS-986365, against standard treatments (chemotherapy or another hormone therapy) in men with metastatic castration-resistant prostate cancer, a type that has spread and stopped responding to hormone therapy. About 960 participants will be randomly as…

This study is testing a combination of two drugs, mezigdomide and elranatamab, in people with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see if the combination is safe and shows early signs of working. Ab…

This study looks at the long-term safety of luspatercept in people with certain blood disorders (MDS, beta-thalassemia, or myelofibrosis) who were already in a luspatercept trial. Participants either continue treatment or enter long-term follow-up to monitor side effects, disease…

This study tests whether a new drug called golcadomide combined with rituximab works better than standard treatments for people with follicular lymphoma that has come back or stopped responding to therapy. About 400 adults who have already had at least one prior treatment will be…

This early-stage study is testing two experimental drugs (iberdomide and CC-99282) added to standard chemotherapy for people with untreated aggressive B-cell lymphoma. About 224 adults will take part to find the safest dose and see if the combinations help shrink tumors. The goal…

This study tests a drug called luspatercept in children aged 6 to 18 with beta-thalassemia, a blood disorder that often requires regular blood transfusions. The goal is to find a safe dose that can reduce the need for transfusions or raise hemoglobin levels. Participants will be …

This study compares a new drug combination (mezigdomide, bortezomib, and dexamethasone) against a standard combination (pomalidomide, bortezomib, and dexamethasone) in about 810 adults with multiple myeloma that has come back or stopped responding to treatment. Participants must …

This expanded access program provides a CAR T-cell therapy called ide-cel to people with multiple myeloma whose specially made treatment batch did not meet commercial standards. The goal is to offer a treatment option when no other suitable therapy is available. Participants must…

This study tests an oral medication (BMS-986368) to reduce agitation in people with Alzheimer's disease. About 120 participants will receive either the drug or a placebo. The main goal is to see if the drug can decrease agitated behaviors like restlessness or aggression, as measu…

This study tests an experimental pill (BMS-986368) to reduce muscle stiffness (spasticity) in people with multiple sclerosis. About 200 adults with MS and leg stiffness will receive one of three doses or a placebo. The main goal is to see if the drug improves muscle tightness and…

This study looks at how two common drugs (itraconazole and rifampin) change the amount of AR-LDD (BMS-986365) in the blood of healthy adult men. About 42 participants will take AR-LDD alone and then with each other drug to compare levels. The goal is to understand drug interactio…

This study follows children and adults who have already received gene-modified T cells in a previous trial. Researchers will watch for long-term side effects, check how long the modified cells stay in the body, and monitor overall survival. No new treatment is given—this is a saf…